مباشر

BioPharma DiveCelcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial Clinical OMICsAI-Powered Blood Test Detects Early Retinal Damage in Diabetes Clinical OMICsMature Intestinal Cells Revert to Stem-Like State to Sustain Colorectal Cancer FierceBiotechFoundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo FierceBiotechNew heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells Endpoints NewsLilly gives hospitals deadline to comply with 340B claims data policy Endpoints NewsFDA details flexibilities for new cell and gene therapies to leverage past data Endpoints NewsAnti-aging biotech NewLimit raises $435M at $3B+ valuation BioPharma DiveEli Lilly issues data sharing ultimatum to 340B hospitals FierceBiotechASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer BioPharma DiveFulcrum exploring a potential sale after FDA sidelined its sickle cell drug Endpoints NewsWhat’s next for VEGF? #ASCO26 offered clues, but answers will have to wait

Endpoints News ٢ يونيو ٢٠٢٦

Anti-aging biotech NewLimit raises $435M at $3B+ valuation

The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-agi...

The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said Tuesday it has raised ...